PHUONG NGUYEN: Open Payments
NPI 1336505064 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,358 in 156 payments from 13 companies in 2025. Trend: 2023 $48 · 2024 $804 · 2025 $4,358
Food & beverage: $4,248Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 24 | $957 |
| Otsuka America Pharmaceutical, Inc. | 23 | $519 |
| Janssen Pharmaceuticals, Inc | 15 | $515 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $446 |
| ABBVIE INC. | 24 | $379 |
| Vanda Pharmaceuticals Inc. | 12 | $338 |
| Alkermes, Inc. | 14 | $334 |
| Braeburn Inc. | 3 | $278 |
| Neurocrine BioSciences, Inc. | 5 | $230 |
| E.R. Squibb & Sons, L.L.C. | 4 | $192 |
Products named: INVEGA SUSTENNA, AUSTEDO XR, CAPLYTA, UZEDY, VRAYLAR, FANAPT, REXULTI, BRIXADI.
Industry payments across PA — which companies pay providers there.
